Summary of Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings as of Dec 8, 2018

Big Money Sentiment increased to 1.24 in 2018 Q2. It has change of 0.32, from 2018Q1’s 0.92. The ratio is positive due to Integra LifeSciences Holdings Corporation positioning: 23 sold and 70 reduced. 48 funds took positions and 67 increased positions. Investors holded 69.24 million in 2018Q1 but now own 70.93 million shares or 2.45% more.
Zeke Cap Advisors Limited Com accumulated 3,163 shs. Qs Limited Liability Co reported 1,308 shs. Plante Moran Financial Advsr Ltd Liability Company has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). California State Teachers Retirement Systems holds 0.02% or 113,027 shs in its capital. 31,800 were reported by Gam Ag. Moreover, Voya Inv Management Limited Liability Com has 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 22,674 are held by Us Bank & Trust De. De Burlo Gp Inc holds 0.16% or 11,954 shs. Parametric Portfolio stated it has 209,707 shs or 0.01% of all its holdings. Credit Suisse Ag accumulated 0% or 47,549 shs. Moreover, Pitcairn Commerce has 0.04% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 156,211 were reported by Rhumbline Advisers. Cardinal Mngmt invested in 0.34% or 17,580 shs. Diversified Trust reported 14,907 shs. Dimensional Fund Ltd Partnership stated it has 0.03% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

A total of 8 analysts rate Integra Lifesciences (NASDAQ:IART) as follows: 2 “Buy”, 5 “Hold” and 1 “Sell”. Тherefore 25% are bullish. (NASDAQ:IART) has 9 ratings reports on Dec 8, 2018 according to StockzIntelligence. The stock rating was downgraded by Bank of America to “Underperform” on Tuesday, August 7. On Monday, July 2 the company was downgraded by Citigroup. On Friday, November 2 the rating was maintained by JMP Securities with “Market Outperform”. On Friday, November 2 the firm has “Neutral” rating given by Citigroup. On Thursday, July 26 BTIG Research upgraded the shares of IART in report to “Buy” rating. The stock rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, October 11. On Thursday, November 1 Wells Fargo maintained the shares of IART in report with “Market Perform” rating. The stock rating was maintained by Cantor Fitzgerald with “Neutral” on Thursday, November 1. Listed here are Integra LifeSciences Holdings Corporation (NASDAQ:IART) PTs and latest ratings.

28/11/2018 Broker: UBS Rating: Neutral New Target: $58 Initiates Coverage On
02/11/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $66 New Target: $60 Maintain
02/11/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $66 New Target: $62 Maintain
01/11/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $61 New Target: $55 Maintain
01/11/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $59 New Target: $54 Maintain
11/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $58 New Target: $68 Maintain
07/08/2018 Broker: Bank of America Old Rating: Neutral New Rating: Underperform Downgrade
26/07/2018 Broker: BTIG Research Old Rating: Neutral New Rating: Buy Old Target: $56 Upgrade
02/07/2018 Broker: Citigroup Old Rating: Buy New Rating: Neutral Old Target: $64 New Target: $66 Downgrade

IART hit $49.96 during the last trading session after $1.03 change.Currently Integra LifeSciences Holdings Corporation is uptrending after 21.16% change in last December 8, 2017. IART has also 452,427 shares volume. IART outperformed the S&P500 by 5.54%.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The company has $4.26 billion market cap. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.51.29 is the P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

For more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news announced briefly go to: Seekingalpha.com, Nasdaq.com, Globenewswire.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Ambac Financial +4.2% on index promotion; IART, EVRG, NAVI changing places – Seeking Alpha” announced on May 31, 2018, “Integra LifeSciences (IART) Tops on Q1 Earnings, ’18 View Up – Nasdaq” on April 26, 2018, “Integra® XT Revision Total Ankle Replacement System Offers Innovative Solution to Ankle Arthroplasty Revision Surgery – GlobeNewswire” with a publish date: November 20, 2018, “Here’s Why You Should Buy Integra LifeSciences (IART) Stock – Nasdaq” and the last “Premarket analyst action – healthcare – Seeking Alpha” with publication date: July 02, 2018.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.